Effects of Purified Newly Developed Botulinum Neurotoxin Type A in Rat Prostate

Urology

Volumn 74, Issue 2, 2009, Pages 436-439

  Nishiyama, Yasuhiro ^a   Yokoyama, Teruhiko ^b   Tomizawa, Kazuhito ^a   Okamura, Kikuo ^a   Yamamoto, Yumiko ^a   Matsui, Hideki ^a   Oguma, Keiji ^c   Nagai, Atsushi ^b   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c National Center for Geriatrics and Gerontology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE; RAT;

ANIMALS; APOPTOSIS; ATROPHY; BOTULINUM TOXIN TYPE A; MALE; NEUROTOXINS; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 67651122991     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.01.047     Document Type: Article

References (15)

1. Chuang Y.C., and Chancellor M.B. The application of botulinum toxin in the prostate. J Urol 176 (2006) 2375-2382
2. Dykstra D.D., Sidi A.A., Scott A.B., et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139 (1988) 919-922
3. Schurch B., Stohrer M., Kramer G., et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs?. Preliminary results. J Urol 164 (2000) 692-697
4. Chuang Y.C., Tu C.H., Huang C.C., et al. Intraprostatic botulinum toxin type A injection relieves bladder outlet obstruction and induces prostate apoptosis in dogs. BMC Urol 6 (2006) 12
5. Chuang Y.C., Chiang P.H., Huang C.C., et al. Botulinum toxin A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66 (2005) 775-779
6. Chuang Y.C., Chiang P.H., Yoshimura N., et al. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98 (2006) 1033-1037
7. Oguma K., Inoue K., Fujinaga Y., et al. Structure and function of Clostridium botulinum progenitor toxin. J Toxicol Toxin Rev 18 (1999) 17-34
8. Lee J.-C., Yokoyama T., Hwang H.-J., et al. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory detrusor overactivity. FEMS Immunol Med Microbiol 51 (2007) 201-211
9. Lepor H., Tang R., and Shapiro E. The α-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 22 (1993) 301-307
10. Ventura S., Pennefather J.N., and Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 94 (2002) 93-112
11. Doggweiler R., Zermann D.-H., and Ishigooka M. Botox-induced prostatic involution. Prostate 37 (1998) 44-50
12. Smith C.P., Franks M.E., McNeil B.K., et al. Effects of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169 (2003) 1896-1901
13. Luján M., Páez A., Llanes L., et al. Role of autonomic innervation in rat prostatic structure maintenance: A morphometric analysis. J Urol 160 (1988) 1919-1923
14. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 19 (2003) 1520-1525
15. Maria G., Brisinda G., Civello I.M., et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62 (2003) 259-264